中国药房2016，Vol.27Issue(33)：4671-4674,4.DOI:10.6039/j.issn.1001-0408.2016.33.22
糖脉康制剂联合常规降糖药治疗糖尿病肾脏病的系统评价
Tangmaikang Preparations Combined with Conventional Hypoglycemic Agents in the Treatment Diabetic Kidney Disease:A Systematic Review
摘要
Abstract
OBJECTIVE:To systematically review the efficacy of Tangmaikang tablet combined with conventional hypolycemic agents in the treatment of diabetic kidney disease,and provide evidence-based reference for clinic. METHODS:Retrieved from Medline,EMBase,Cochrane Library,CBM,CJFD,Wanfang Database and VIP,randomized controlled trials(RCT)about Tang-maikang tablet combined with western medicine(test group)versus western medicine alone(control group)in the treatment of dia-betic kidney disease were collected. Meta-analysis was performed by Rev Man software after data extraction and quality evaluation. RESULTS:Totally 9 RCTs were included,involving 883 patients. Results of Meta-analysis showed,the clinical effective rate in test group were significantly higher than control group [OR=4.88,95%CI(2.56,9.32),P<0.001],Scr level[MD=-28.48,95%CI (-34.90,22.06),P<0.001] and 24 h urinary protein excretion [MD=-100.26,95%CI(-106.00,-94.52),P<0.001],with sta-tistical significance;there was no significant difference in BUN level in 2 groups [MD=-0.85,95%CI(-1.36,-0.34),P=0.001]. CONCLUSIONS:Tangmaikang granule/tablet combined with conventional hypoglycemic agents has good efficacy in the treatment of diabetic kidney disease,which can reduce patients’Scr and 24 h urinary protein excretion.关键词
糖尿病肾脏病/糖脉康颗粒/糖脉康片/系统评价/疗效Key words
Diabetic kidney disease/Tangmaikang granule/Tangmaikang tablet/Systematic review/Eifficacy分类
医药卫生引用本文复制引用
郭强,陈秋,赵欢,雷星星,鲁燕,王胜菊,方威,祖义志,唐小妹,祝然然..糖脉康制剂联合常规降糖药治疗糖尿病肾脏病的系统评价[J].中国药房,2016,27(33):4671-4674,4.基金项目
国家中医药管理局全国名老中医药专家传承工作室建设项目（No.国中医药人教发〔2014〕20号）；国家中医药管理局中医药标准化项目 （）
